Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Ramiro, S (författare)

Sepriano, A (författare)

Nam, JL (författare)

Smolen, JS (författare)

van der Heijde, D (författare)

Dougados, M (författare)

Bijlsma, JW (författare)

Burmester, GR (författare)

Scholte-Voshaar, M (författare)

Falzon, L (författare)

Landewe, RBM (författare)

(creator_code:org_t)

2017-03-15
2017
Engelska.
Ingår i: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 76:6, s. 1093-1101

Relaterad länk:: https://ard.bmj.com/...; visa fler...; http://kipublication...; https://doi.org/10.1...; visa färre...

Abstract Ämnesord

Stäng

To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA.MethodsSystematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included. Risk of bias was assessed with the Hayden's tool.ResultsTwenty-six observational studies addressing diverse safety outcomes of therapy with bDMARDs met eligibility criteria (15 on serious infections, 4 on malignancies). Substantial heterogeneity precluded meta-analysis. Together with the evidence from the 2013 SLR, based on 15 studies, 7 at low risk of bias, patients on bDMARDs compared with patients on conventional sDMARDs had a higher risk of serious infections (adjusted HR (aHR) 1.1 to 1.8)—without differences across bDMARDs—a higher risk of tuberculosis (aHR 2.7 to 12.5), but no increased risk of infection by herpes zoster. Patients on bDMARDs did not have an increased risk of malignancies in general, lymphoma or non-melanoma skin cancer, but the risk of melanoma may be slightly increased (aHR 1.5).ConclusionsThese findings confirm the known safety pattern of bDMARDs, including both tumour necrosis factor-α inhibitor (TNFi) and non-TNFi, for the treatment of RA.

Av författaren/redakt...: Ramiro, S; Sepriano, A; Chatzidionysiou, ...; Nam, JL; Smolen, JS; van der Heijde, ...; visa fler...; Dougados, M; van Vollenhoven, ...; Bijlsma, JW; Burmester, GR; Scholte-Voshaar, ...; Falzon, L; Landewe, RBM; visa färre...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.